Core One Labs

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Core One Labs has already paid €0.11 in dividends. The last payout was in June 2022.

Financials

In the last year, Core One Labs had revenue of €315.03K and net profit of -€10.98M

(EUR)	2022	YoY
Revenue	315.03K	4.90%
Gross profit	286.04K	4.65%
Net profit	-10.98M	57.41%
EBITDA	-5.36M	36.57%

Fundamentals

Metric	Value
Market capitalization	€418.48
Number of shares	47.1M
52-week high/low	€0.0161 - €0.0000009
Dividends	No
Beta	0.54
P/E ratio	-0.28
PEG ratio	0.00
P/B ratio	0.66
P/S ratio	14.89

Company profile

Core One Labs Inc. operates as a biotechnology research and technology life sciences company. The company focuses on bringing psychedelic medicines to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Its CannaStrips technology produces infused strips that allow for bioavailability of cannabis constituents. The company also offers consulting, financing, and micro cultivation services, as well as operates medical and wellness clinics. In addition, it provides natural health products; and news dissemination services. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

Name	Core One Labs
CEO	Gareth Manderson
Headquarters	Vancouver, bc Canada
Website	core1labs.com
Sector	Health Care
Industry	Biotechnology
IPO	07/11/2016
Employees	192